Immunome Inc Aktie News

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical data showing its proprietary antibody-drug conjugate (ADC) payload HC74 overcomes multiple mechanisms of ADC resistance, including payload efflux and target heterogeneity. HC74 is a novel topoisom...

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Oct. 1, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase...

Immunome, Inc (NASDAQ: IMNM) has a “rich pipeline of potential best and/or first-in-class targeted oncology therapeutics,” Goldman Sachs analysts wrote in a note to clients on Monday.   They initiated coverage on Immunome stock with a ‘Buy' rating and 12-month target price of $26 per share.

ALAMEDA, Calif.--(BUSINESS WIRE)-- #antibodies--Infinimmune Announces Research Collaboration with Immunome.

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Sept. 2, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchas...

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, Sept. 9, 2025 at 1:00 p.m. Eastern Time. Interested parties can access the live audio webcast for...

Immunome's lead asset, varegacestat, shows promising efficacy in desmoid tumors, with phase 3 topline data expected by the end of 2025. IMNM holds Orphan Drug designations in the US and Europe, potentially enabling accelerated approval if phase 3 results are positive. Cash reserves of $143.9M and marketable securities of $124.2M provide runway into 2027, despite a high annualized cash burn.

Immunome (IMNM -3.59%), a clinical-stage biotechnology company developing targeted therapies for cancer, reported its second quarter 2025 earnings on August 6, 2025. The standout news was a substantial revenue beat, with $4.0 million in GAAP revenue topping analyst forecasts by a wide margin, plus a narrower-than-expected GAAP loss per share.